HCFA Makes Public Near-Final Coverage Decisions On Three Devices
This article was originally published in The Gray Sheet
Executive Summary
The first evidence of a more open Medicare coverage process appeared on the Health Care Financing Administration's web site Feb. 3, as the agency posted coverage information for four devices: cardiac monitoring by electrical bioimpedance, external counterpulsation, transmyocardial revascularization, and positron emission tomography.
You may also be interested in...
Electrical bioimpedance for hypertension NCD
Thoracic electrical bioimpedance (TEB) for treating drug-resistant hypertension is left to local carrier discretion, CMS states in an 1Aug. 7 national coverage determination decision memo. On the same day, the agency issued a national non-coverage policy for TEB in managing all other forms of hypertension. Six indications of TEB are already covered under an NCD (2"The Gray Sheet" Feb. 8, 1999, p. 7). CardioDynamics offers the BioZ impedance cardiography (ICG) test...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.